Hospira Recalls Propofol Injectable Emulsion Lot Due to Potential Particulate Risk

Pfizer subsidiary Hospira has recalled one lot of its Propofol intravenous anesthetic because of the potential presence of a particulate observed in a single vial from retained samples.

Patients receiving the affected product are at risk of life-threatening adverse effects, including blocked blood vessels, decreased blood flow to the brain, heart attack, pulmonary embolus and tissue necrosis, the FDA said.

The affected lot of a 100 mL single patient use glass vial, lot DX9067, was distributed nationwide between June 10, 2020 and June 26, 2020. Hospira has not received any reports of adverse events associated with this issue for the specific lot.